Home >> Behavioral Health >> Behavioral Health >> Baby Food >> Technology & Media >>

Nippon Kayaku Co., Ltd. Product Pipeline Review 2012

Published: Oct-2012 | Format: PDF | Global Markets Direct | Number of pages: 55 | Code: MRS - 828

Global Market Directs pharmaceuticals report, Nippon Kayaku Co., Ltd. Product Pipeline Review 2012 provides data on the Nippon Kayaku Co., Ltd.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Directs proprietary databases, Nippon Kayaku Co., Ltd.s corporate website, SEC filings, investor presentations and featured press releases, both from Nippon Kayaku Co., Ltd. and industry-specific third party sources, put together by Global Markets Directs team.

Scope


Nippon Kayaku Co., Ltd. Brief Nippon Kayaku Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of Nippon Kayaku Co., Ltd. human therapeutic division.
Overview of pipeline therapeutics across various therapy areas.
Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
Product profiles for late stage and clinical stage products of Nippon Kayaku Co., Ltd. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones.
Recent updates of the Nippon Kayaku Co., Ltd.s pipeline in the last quarter.
Key discontinued and dormant projects.
Latest news and deals relating to the products.

Reasons to buy

Evaluate Nippon Kayaku Co., Ltd.s strategic position with total access to detailed information on its product pipeline.
Assess the growth potential of Nippon Kayaku Co., Ltd. in its therapy areas of focus.
Identify new drug targets and therapeutic classes in the Nippon Kayaku Co., Ltd.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
Exploit collaboration and partnership opportunities with Nippon Kayaku Co., Ltd..
Avoid Intellectual Property Rights related issues.
Explore the dormant and discontinued projects of Nippon Kayaku Co., Ltd. and identify potential opportunities in those areas.

Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Nippon Kayaku Co., Ltd. Snapshot 5
Nippon Kayaku Co., Ltd. Overview 5
Key Information 5
Key Facts 5
Vectura Group plc Research and Development Overview 6
Key Therapeutic Areas 6
Vectura Group plc Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products Monotherapy 10
Pipeline Products Combination Treatment Modalities 11
Vectura Group plc Pipeline Products Glance 12
Vectura Group plc Late Stage Pipeline 12
Filing Rejected/Withdrawn Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
Vectura Group plc Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Vectura Group plc Drug Profiles 16
apaziquone 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
fentanyl citrate 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
gusperimus trihydrochloride 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
NK-012 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
NK012 + 5-Fluorouracil + Leucovorin 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
NK012 + Carboplatin 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ozarelix 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
paclitaxel 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Vectura Group plc Pipeline Products by Route of Administration 30
Vectura Group plc Pipeline Products By Mechanism of Action 31
Vectura Group plc Recent Pipeline Updates 32
Vectura Group plc - Dormant Projects 34
Vectura Group plc Company Statement 35
Vectura Group plc Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Financial Deals Landscape 39
Nippon Kayaku Co., Ltd., Deals Summary 39
Nippon Kayaku Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 40
Venture Financing 40
NanoCarrier Secures $3.39 Million In Mezzanine Funding Round 40
Partnerships 42
Teva-KOWA Pharma Enters Into Agreement With Nippon Kayaku 42
BioSphere Medical Enters Into An Agreement With Nippon Kayaku 43
Toyota Tsusho America Forms Joint Venture With Nippon Kayaku 44
Nihon Medi-Physics Enters Into Co-Marketing Agreement With Nippon Kayaku 45
Nippon Kayaku Enters Into An Agreement With KYUKYU Pharma 46
Licensing Agreements 47
Nordic Pharma Enters Into Licensing Agreement With Nippon Kayaku For Spanidin 47
Spectrum Pharma Enters Into Licensing Agreement With Nippon Kayaku 48
AEterna Enters Into License And Collaboration Agreement With Nippon Kayaku For Ozarelix 50
Asset Transactions 52
Sanofi-aventis Acquires Rights To ImmuCyst From Nippon Kayaku 52

Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55


List of Tables


Nippon Kayaku Co., Ltd., Key Information 5
Nippon Kayaku Co., Ltd., Key Facts 5
Vectura Group plc Pipeline by Indication, 2012 8
Nippon Kayaku Co., Ltd. Pipeline by Stage of Development, 2012 9
Nippon Kayaku Co., Ltd. Monotherapy Products in Pipeline, 2012 10
Nippon Kayaku Co., Ltd. Combination Treatment Modalities in Pipeline, 2012 11
Vectura Group plc Filing Rejected/Withdrawn, 2012 12
Vectura Group plc Phase III, 2012 13
Vectura Group plc Phase II, 2012 14
Vectura Group plc Phase I, 2012 15
Nippon Kayaku Co., Ltd. Pipeline By Route of Administration, 2012 30
Nippon Kayaku Co., Ltd. Pipeline Products By Mechanism of Action, 2012 31
Vectura Group plc Recent Pipeline Updates, 2012 32
Vectura Group plc - Dormant Developmental Projects,2012 34
Nippon Kayaku Co., Ltd., Subsidiaries 36
Nippon Kayaku Co., Ltd., Deals Summary 39
NanoCarrier Secures $3.39 Million In Mezzanine Funding Round 40
Teva-KOWA Pharma Enters Into Agreement With Nippon Kayaku 42
BioSphere Medical Enters Into An Agreement With Nippon Kayaku 43
Toyota Tsusho America Forms Joint Venture With Nippon Kayaku 44
Nihon Medi-Physics Enters Into Co-Marketing Agreement With Nippon Kayaku 45
Nippon Kayaku Enters Into An Agreement With KYUKYU Pharma 46
Nordic Pharma Enters Into Licensing Agreement With Nippon Kayaku For Spanidin 47
Spectrum Pharma Enters Into Licensing Agreement With Nippon Kayaku 48
AEterna Enters Into License And Collaboration Agreement With Nippon Kayaku For Ozarelix 50
Sanofi-aventis Acquires Rights To ImmuCyst From Nippon Kayaku 52 

List of Figures

Nippon Kayaku Co., Ltd. Pipeline by Indication, 2012 7
Nippon Kayaku Co., Ltd. Pipeline by Stage of Development, 2012 9
Nippon Kayaku Co., Ltd. Monotherapy Products in Pipeline, 2012 10
Nippon Kayaku Co., Ltd. Combination Treatment Modalities in Pipeline, 2012 11
Nippon Kayaku Co., Ltd. Pipeline By Route of Administration, 2012 30
Nippon Kayaku Co., Ltd. - Pipeline Products By Mechanism of Action, 2012 31 

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing